|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300072842 |
|
最近更新日期: Date of Last Refreshed on: |
2023-06-26 17:18:39 |
|
注册时间: Date of Registration: |
2023-06-26 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
B超引导平卧位双侧QLB的去OFA对下腹部手术麻醉疗效探索 |
|
Public title: |
Study on the efficacy of OFA in lower abdominal surgery with B-ultrasound-guided QLB in supine position |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
B超引导平卧位双侧QLB的去OFA对下腹部手术麻醉疗效探索 |
|
Scientific title: |
Study on the efficacy of OFA in lower abdominal surgery with B-ultrasound-guided QLB in supine position |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
代景伟 |
研究负责人: |
代景伟 |
|
Applicant: |
DAI Jingwei |
Study leader: |
DAI Jingwei |
|
申请注册联系人电话: Applicant telephone: |
+86 158 0892 8236 |
研究负责人电话:
Study leader's |
+86 158 0892 8236 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
daijingwei2021@163.com |
研究负责人电子邮件: Study leader's E-mail: |
daijingwei2021@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
海南省万宁市环市三东路1号 |
研究负责人通讯地址: |
海南省万宁市环市三东路1号 |
|
Applicant address: |
1 Huanshi SAN Dong Road, Wanning City, Hainan Province, China |
Study leader's address: |
1 Huanshi SAN Dong Road, Wanning City, Hainan Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
571500 |
研究负责人邮政编码: Study leader's postcode: |
571500 |
|
申请人所在单位: |
海南省万宁市人民医院 |
||
|
Applicant's institution: |
Hainan Wanning People's Hospital |
||
|
研究负责人所在单位: |
海南省万宁市人民医院 |
||
|
Affiliation of the Leader: |
Hainan Wanning People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SL-2021-002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
海南省万宁市人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Hainan Wanning People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-02-22 00:00:00 | ||
|
伦理委员会联系人: |
林学斌 |
||
|
Contact Name of the ethic committee: |
LIN Xuebin |
||
|
伦理委员会联系地址: |
海南省万宁市环市三东路1号 |
||
|
Contact Address of the ethic committee: |
1 Huanshi SAN Dong Road, Wanning City, Hainan Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 898 6222 0279 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
海南省万宁市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hainan Wanning People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
海南省万宁市环市三东路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1 Huanshi SAN Dong Road, Wanning City, Hainan Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
海南省科学技术厅 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hainan Provincial Department of Science and Technology |
||||||||||||||||||||||
|
研究疾病: |
超声引导腰方肌+腹横肌阻滞对下腹部手术的去阿片化麻醉 |
||||||||||||||||||||||
|
Target disease: |
Ultrasound-guided QLB+ TAPfor OFA in lower abdominal surgery |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
基于B超引导双侧腰方肌+双侧腹横肌阻滞联合喉罩全凭静脉全麻行腹腔镜下腹部手术的临床疗效,是否可完全代替阿片类药物或节约阿片类药物。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on the clinical effect of B-ultrasound guided bilateral QLB + TAP combined with laryngeal mask for laparoscopic abdominal surgery under intravenous general anesthesia,Whether opioids can be completely replaced or saved. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄18-65岁;ASAⅠ-III级患者(2)肝肾功能正常,术后计划住院≥48h;(3)行下腹部和或盆腔,开放或腔镜手术(4)无本实验所用药物过敏史。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Aged 18-65 years; ASA Grade I-III patients (2) had normal liver and kidney function and were scheduled to be hospitalized for ≥48h after surgery; (3) The lower abdomen or pelvis, open or endoscopic surgery was performed. (4) There was no history of allergy to the drugs used in this study. |
||||||||||||||||||||||
|
排除标准: |
排除标准:(1)拒绝签署知情同意书(2)患有严重的循环功能不全、心律失常(尤其是缓慢性心律失常)、低血容量、休克、冠状动脉不稳定、自主神经病变伴直立性低血压(3)安装起搏器及术前长期口服β受体阻滞剂者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Refuse to sign informed consent or participate in the study. (2) Have severe circulatory insufficiency, arrhythmia (especially bradycardia), hypovolemia, shock, coronary instability, autonomic neuropathy with orthostatic hypotension. (3) Mental illness and chronic pain that may confuse analgesia. (4) inability to communicate or difficulty communicating. (5) have blood pressure Or severe risk of elevated intracranial pressure (6) poorly controlled or untreated hypertension > 180/100 MMHG (7) untreated or undertreated hyperthyroidism. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-09-29 00:00:00至 To 2023-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-10-01 00:00:00 至 To 2022-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
同一麻醉护士采用随机数字表法计算机分配 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The same anesthetized nurse was assigned by computer with random number table method. The singular number was the experimental group and the even number was the control group |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
将配置好未贴标签的0.5%利多卡因+0.20%罗哌卡因40mL或0.9%NS40mL、分组标签分别装入不同的两个密闭不透光的信封中交给当值麻醉医生。 |
|
Blinding: |
The unlabeled 0.5% lidocaine and 0.20% ropivacaine 40mL or 0.9%NS40mL were packed into two different airtight envelopes and handed to the anesthesiologist on duty. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台 IPD(http://www.medresman.org.cn)。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan IPD (http://www.medresman.org.cn) . |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1.病例文件中的打印麻醉记录单 2.手麻系统的电子麻醉记录单 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. Print the anesthesia record sheet in the case file 2. Electronic anesthesia record sheet of manual anesthesia system |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |